

AMENDMENTS

Amendments to the Specification:

Please amend the first full paragraph on p. 18 to recite as follows:

The term "specific binding" (and equivalent phrases) refers to the ability of a binding moiety (e.g., a receptor, antibody, or antiligand) to bind preferentially to a particular target molecule (e.g., ligand or antigen) in the presence of a heterogeneous population of proteins and other biologics (i.e., without significant binding to a other components present in a test sample). Typically, specific binding between two entities, such as a ligand and receptor, means a binding affinity of at least about $4 \times 10^6 M^{-1} 10^{-6} M$, and preferably at least about $4 \times 10^7, 10^8, 10^9, \text{ or } 10^{10} M^{-1} 10^{-7}, 10^{-8}, 10^{-9}, \text{ or } 10^{-10} M$. In some C1 embodiments specific binding is assayed (and specific binding molecules identified) according to the method of U.S. Patent No. 5,622,699; (this reference and all references cited therein are incorporated herein by reference). Typically, a specific or selective reaction according to this assay is at least about twice background signal or noise and more typically at least about 5 or at least about 100 times background, or more.

Please amend the first paragraph on p. 27 to recite as follows:

(B) Preferred Targeting Molecules

Preferred targeting molecules of the invention comprise an amino acid sequence selected from the group comprising GGGVFWQ, HGRVRPH, VVLVTSS, CLHRGNSC, and CRSWNKADNRSC (SEQ ID NO:1-5, respectively) using the *in vivo* panning procedure described above and referenced below. The GGGVFWQ, HGRVRPH, VVLVTSS, and CLHRGNSC (SEQ ID NO:1-4, respectively) peptides selectively bind to normal cardiac endothelium. More specifically, the GGGVFWQ (SEQ ID NO:1) peptide showed a 5-fold enrichment to normal cardiac vasculature, while the HGRVRPH, VVLVTSS, CLHRGNSC (SEQ ID NO:2-4, respectively) peptides showed a 2-fold enrichment to normal cardiac vasculature. The CRSWNKADNRSC (SEQ ID NO:5)

C2

peptide showed 5-fold enrichment to ischemic myocardium. Details of how these peptides were identified and their properties are described in U.S.S.N. _____
Cz A
[Campbell & Flores LLP Attorney Docket # P-JL 3512] U.S.S.N. 09/326,718, now issued
as U.S. Patent No. 6,303,573, filed on even date herewith which is specifically
incorporated herein by reference.
